Randomized Trialhigh evidence
Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 10-year efficacy and late normal tissue effects from a multicentre, open-label, non-inferiority, phase 3, randomised controlled trial and 5-year efficacy results from a randomised axillary substudy.
The Lancet. Oncology·June 1, 2026·PMID 42134381
Why it mattersThis provides long-term evidence that a 1-week schedule is safe and effective, supporting its adoption as a standard of care. It reduces treatment burden for patients and healthcare systems without compromising outcomes.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled